Table 1.
Studies Investigating the Expression of p53 in Renal Cell Carcinoma
| Study | No. of Specimens (% CCRCC) |
Antibody | Positive Criteria, % |
No. Positive (%) |
p53 Prognostic Value |
Comments |
|---|---|---|---|---|---|---|
| Klatte 200924 | 170 (100); All stages; M=0 | ?a | Any | ?a | Yes | Decreased DFS |
| Perret 200825 | 50 (0) All PRCC; 25 type I/25 type II; M=8 |
DO-7 | >20 | 24 (48); Type I=12/type 2=36 |
Yes | Decreased OS in type II PRCC |
| Phuoc 200726 | 119 (100); All stages; M=23 | DO-7 | >10 | 64 (54) | Yes | Decreased DSS in all patients |
| Kankuri 200627 | 117 (86); All stages; M=29 | DO-7 | >10 | 15 (12.8) | Yes | Decreased OS in patients with metastases |
| Kramer 200528 | 117 (89); All stages; M=21 | ?a | >5 | 16 (13.6) | No | |
| Langner 200529 | 95 (75); stage pT1 only; M=0 | DO-7 | ?a | 23 (24) | Not evaluated | |
| Cho 200530 | 92 (100); All stages; M=7 | ?a | >10 | 11 (12) | Yes | Decreased DSS |
| Shvarts 200531 | 193 (85); All stages; M=0 | DO-7 | Any, >20 | 111 (57.5), 14 (7.3) | Yes | 20% Cutoff predicted recurrence |
| Uzunlar 200532 | 57 (77.1); All stages and grades; M=? | ?a | >1 | 20 (35) | Yes | Decreased DSS |
| Zigeuner 200433 | 184 (70.7)/Metastases, 56 (94.8)b | DO-7 | >1 | 42 (22.8)/29 (51.8) | Yes | Decreased metastasis-free survival in CCRCC only |
| Kim 200434 | 318; All stages; M=155 | DO-7 | >15 | ?a | Yes | Decreased DSS |
| Uchida 200235 | 112 (78); All stages; M=? | DO-7 | >1 | 15 (13.4) | Yes | Decreased OS |
| Olumi 200136 | 43 (100); All stages; M=14 | DO-7/PAB240/both | >10, Either | 22 (51)/13 (30)/26 (60) | No | Combined antibody positivity was 60% |
| Ljungberg 200137 | 99 (74); All stages; M=? | DO-7 | >5 | 17 (19) | Yes | Decreased survival in non-CCRCC |
| Girgin 200138 | 50 (62); All stages; M=0 | DO-1 | >20 | 16 (20) | Yes | Decreased disease-specific death |
| Haitel 200039 | 97 (100); All stages; M=15 | DO-1 | >5 | 35 (36) | Yes | Decreased DSS |
| Rioux-Leclercq 200040 | 66 (?); All stages; M=10 | DO-7 | >20 | 11 (17) | Yes | Decreased DSS |
| Sejima & Miyagawa 199941 | 53 (?); All stages; M=25 | RSP53 | ?a | 1 (2) | No | |
| Vasavada 199842 | 39 (71); T1 and T2 only; M=0 | DO-7 | >1 | 0 | No | |
| Sinik 199743 | 39 (100); All stages; M=? | DO-7 | >10 | 7 (17.9) | No | |
| Papadopoulos 199744 | 90 (?); T1 and T2; M=14 | DO-1 | Any positive nuclei | 30 (33) | No | |
| Zhang 199745 | 70 (?); All stages; M=? | Ab-6 | >10 | 16 (23) | Not evaluated | |
| Gelb 199746 | 52 (100); T1 and T2 only; M=0 | DO-7 | >5 | 2 (2) | No | |
| Shiina 199747 | 72 (?); All stages; M=6 | DO-7 | >10 | 29 (40.3) | Yes | Decreased OS |
| Moch 199748 | 50 (100); T3 only; M=1 | DO-7 | ?a | 8 (16) | Yes | Decreased OS |
| Hofmockel 199649 | 31 (?); T1-T3; M=0 | DO-7 | >1% | 5 (16) | No | |
| Chemeris 199550 | 82 (40)c; M=? | DO-1 | ?a | 43 (52) | Not evaluated | |
| Lipponen 199451 | 123 (?); M=29 | CM1 | Any positive | 41 (33) | Yes | Increased recurrence-free survival |
| Kamel 199452 | 56 (?); All stages; M=13 | CM1 | >1 | 6 (11) | No | |
| Bot 199453 | 100 (74); T1-T3 only; M=0 | DO-7 | >50 | 32 (32) | No | |
| Uhlman 199454 | 175 (?); All stages; M=45 | ?a | >1 | 49 (28) | Yes | Decreased DSS |
CCRCC indicates clear cell renal cell carcinoma; PRCC, papillary renal cell carcinoma; M, metastatic disease; DFS, disease-free survival; OS, overall survival; DSS, disease-specific survival; pT1, pathologic T1 tumor classification.
a
Information not provided.
b
In addition to 184 renal cancers, 56 surgically removed metastatic tissues were analyzed.
c
Thirty-three CCRCCs and 47 clear/chromophilic renal cell carcinomas.